Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 534

1.
2.

Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.

Hara I, Miyake H, Takechi Y, Eto H, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S; Kobe Urogenital Tumor Study Group.

Int J Urol. 2003 Jan;10(1):19-24.

3.
5.

[Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].

Xu C, Jiang XZ, Zhang NZ, Ma L, Xu ZS.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):609-12. doi: 10.3760/cma.j.issn.0253-3766.2012.08.011. Chinese.

PMID:
23158996
6.

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.

Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T; Cancer Registration Committee of the Japanese Urological Association.

Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.

7.

Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.

Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, Masedu F, Ricci AR, Micali F, Vespasiani G.

Lancet Oncol. 2011 Sep;12(9):871-9. doi: 10.1016/S1470-2045(11)70190-5. Epub 2011 Aug 8.

PMID:
21831711
8.

[Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].

Li Q, Xu T, Wang XF.

Zhonghua Zhong Liu Za Zhi. 2009 Dec;31(12):904-7. Chinese.

PMID:
20193328
9.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
10.

[Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].

Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.

Hinyokika Kiyo. 2004 Nov;50(11):767-71. Japanese.

PMID:
15628536
11.

Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y.

J Clin Oncol. 2013 Apr 10;31(11):1422-7. doi: 10.1200/JCO.2012.45.2128. Epub 2013 Mar 4.

12.

Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer.

Onozawa M, Miyanaga N, Hinotsu S, Miyazaki J, Oikawa T, Kimura T, Takaoka E, Kawai K, Shimazui T, Sakurai H, Nishiyama H, Akaza H.

Jpn J Clin Oncol. 2012 Sep;42(9):825-30. doi: 10.1093/jjco/hys105. Epub 2012 Jul 10.

13.

Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.

Lüftenegger W, Ackermann DK, Futterlieb A, Kraft R, Minder CE, Nadelhaft P, Studer UE.

J Urol. 1996 Feb;155(2):483-7.

PMID:
8558641
14.

[Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].

Kuroda K, Ishii N, Fukasawa K, Shirai M, Tajima M, Matsushima M, Miura K, Takanami M, Matsuhashi M, Kuwabara T, Matsumoto H, Sugita M.

Hinyokika Kiyo. 1998 Aug;44(8):547-52. Japanese.

PMID:
9783189
15.

Results of transurethral resection plus adjuvant intravesical chemotherapy for superficial bladder cancer.

Nomi M, Gohji K, Okamoto M, Takenaka A, Ono Y, Fujii A.

Int J Urol. 1998 Nov;5(6):534-9.

16.

Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.

Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, Sandri SD, Nativ O, Colombo R.

Urol Oncol. 2011 May-Jun;29(3):259-64. doi: 10.1016/j.urolonc.2009.02.012. Epub 2009 Apr 22.

PMID:
19395285
17.

Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.

Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.

Anticancer Res. 2002 Nov-Dec;22(6B):3759-64.

PMID:
12552989
18.

[Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].

Fujimoto K, Chihara Y, Kondo H, Hirao Y.

Hinyokika Kiyo. 2006 Jun;52(6):433-8. Japanese.

PMID:
16848356
19.

[A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].

Hashimura T, Shirahase T, Inoue T, Yamasaki T, Terada N, Ogura K, Arai Y, Hida S, Ueda T.

Hinyokika Kiyo. 2005 Jul;51(7):439-42. Japanese.

PMID:
16119805
Items per page

Supplemental Content

Write to the Help Desk